Krill oil and carotenoid composition, associated method and delivery system

Abstract

A medicine delivery system includes an inner capsule containing carotenoids and an outer capsule in which the inner capsule is contained within the outer capsule and the outer capsule containing a therapeutically effective amount of krill oil. In one example, the carotenoids comprise at least S, S′-astaxanthin derived from Haematococcus pluvialis, and one or more of lutein and / or trans-zeaxanthin or meso-zeaxanthin. The medicine delivery system also includes 0.5 to 8 mg of astaxanthin, 2 to 15 mg of lutein and 0.2 to 12 mg of trans-zeaxanthin contained within the inner capsule. In a specific example, the medicine delivery system includes about 4 mg of astaxanthin, about 10 mg of lutein and about 1.2 mg of trans-zeaxanthin contained within the inner capsule.

Description

RELATED APPLICATION(S)[0001]This application is a continuation-in-part of U.S. patent application Ser. No. 12 / 840,396 filed Jul. 21, 2010, which is based on provisional patent application Ser. No. 61 / 227,881, filed Jul. 23, 2009.FIELD OF THE INVENTION[0002]The present invention relates to a krill oil and carotenoid composition used for eye care or other medical applications and medicine delivery system for the composition. The present invention also relates to a method of preventing, retarding and ameliorating central nervous system and eye diseases, including treating eye insult resulting from disease or injury, such as age-related macular degeneration, photic injury, photoreceptor cell or ganglion cell damage, ischemic insult-related diseases, cataracts, dry eye syndromes and inflammatory diseases.BACKGROUND OF THE INVENTION[0003]The eye is an extension of the brain, and therefore a part of the central nervous system. Accordingly, in the case of an eye injury or disease, i.e., a r...

AI Technical Summary

Benefits of technology

The patent describes a medicine delivery system that includes a inner capsule containing carotenoids (which are found in seaweed) and an outer capsule containing krill oil (which contains phospholipid bound and triglyceride bound EPA and DHA). The carotenoids and krill oil are combined to create a synergistic effect that works in the body to treat illnesses. The patent also describes a specific composition that includes about 4 mg of astaxanthin, 10 mg of lutein, and 1.2 mg of trans-zeaxanthin. The method of treatment involves administering this combination to individuals. The technical effects of this patent are a more effective treatment for illnesses and a specific composition that targets specific ingredients for effectiveness.

Problems solved by technology

Accordingly, in the case of an eye injury or disease, i.e., a retinal injury or disease, the diseases are often without treatment and the eye cannot be transplanted.

It has been hypothesized that a major cause of these untreatable retinal and other eye diseases and injuries is the generation and presence of singlet oxygen and other free radical species.

Therefore, some untreatable diseases and injuries to the eye result from the continuous exposure of the eye to light, coupled with the highly-oxygenated environment in the eye.

Excessive light energy reaching the retina can cause damage to these neurons, either directly or indirectly, by overwhelming the metabolic systems of these cells.

These free radical species can lead to functional impairment of the cell membranes and cause temporary or permanent damage to retinal tissue.

In addition, a deficiency in removing these reactive free radical species can also contribute to various diseases of the eye.

However, after cataract extraction or other surgical intervention, some of these protective barriers are removed or disturbed, whereby the photoreceptor cells are more susceptible to damage by radiant energy.

Even though several protective mechanisms are present in the eye, a leading cause of blindness in the United States is age-related photoreceptor degeneration.

Unlike cataracts which can be restored by replacing the diseased lens, age-related macular degeneration cannot be treated by replacing the diseased retina because the retina is a component of the central nervous system.

In addition to photic injury, eye injury and disease can result from singlet oxygen and free radical species generated during reperfusion after an ischemic insult.

Mammals also have a limited ability to modify carotenoids.

However, an undesirable side effect in individuals that ingested canthaxanthin at high doses for an extended time was the formation of crystalline canthaxanthin deposits in the inner layers of the retina.

The carotenoids other than zeaxanthin and lutein that do enter the retina cause adverse effects, such as the formation of crystalline deposits by canthaxanthin, which may take several years to dissolve.

Even though the carotenoids are strong antioxidants, investigators have failed to find particular carotenoids among the 600 naturally-occurring carotenoids that effectively quench singlet oxygen and scavenge for free radical species, that are capable of crossing the blood-retinal brain barrier, that do not exhibit the adverse affects of canthaxanthin after crossing the blood-retinal brain barrier, and that ameliorate eye disease or injury and / or retard the progression of a degenerative disease of the eye and are more potent anti-oxidants than either lutein or zeaxanthin.

To date, investigative efforts have been directed to preventing diseases and injury because the resulting free radical-induced damage is not effectively treatable.

Images